SecBot SecBot

TDAC

Translational Development Acquisition Corp.
Nasdaq· Blank Checks· CIK 0001926599 Traditional Finance
$10.85 +0.04 (+0.37%)
Oct 26 4:00 PM ET · prev $10.81
Next earnings
Nov 12
in 16 days
1 year
+4.0%
from $10.43 · Oct 27
30 days
0.0%
from $10.85
52-week range
$10.40–10.90
−0% from high · low Oct 28
Avg volume 20D
7.9K
Oct 13 spike 35.9K
Short interest
🔒 Subscribers only
Insider net
+$42.3K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 12, 2026
Strongest NEUTRAL Prologium Holding Inc. filed a Rule 425 communication with a press release unveiling its GEN4 Dynamic…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $42.3K. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 3 added (0 new), 2 trimmed or exited.

  • TrendRANGE

    0% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
LINDEN ADVISORS LPADD1,150,000$12.3M
Centiva Capital, LPADD250,000$2.7M
Schonfeld Strategic Advisors LLCTRIM98,630$1.1M
Verition Fund Management LLCTRIM46,687$499.1K
Clear Street Group Inc.DOUBLED4,963$53.1K

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
TDAC Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Oct 1, 2026
Clinical Trial
Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma
Phase 2 · TERMINATED
Aug 12, 2026
Earnings date
TDAC Q2 2026 Earnings Scheduled — 2026-08-12
Jul 6, 2026
Press release
TDAC Announces ProLogium's Filing of F-4 As Continuing Momentum Towards Merger
NEW YORK, July 6, 2026 /PRNewswire/ -- Translational Development Acquisition Company (NYSE: TDAC) ( "TDAC") announced that ProLogium has filed their…
May 13, 2026
Earnings date
TDAC Q1 2026 Earnings Scheduled — 2026-05-13
Mar 16, 2026
Earnings date
TDAC Q4 2025 Earnings Scheduled — 2026-03-16

Insider ledger

Form 4
$42.3K
bought · 1 insider
$0
sold · 0 insiders
DateInsiderTypeValue
May 27, 2026
Hoffman Michael B
Chairman and CEO
BUY$42.3K

Earnings setup

Estimates
Nov 12
reports in 16 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 8, 2026 SEC
Prologium Holding Inc. filed a Rule 425 communication with a press release unveiling its GEN4 Dynamic Coordination…
425 — Impact 3/10
Aug 12, 2026 Earnings calendar
TDAC Q2 2026 Earnings Scheduled — 2026-08-12
Jul 27, 2026 SEC
TDAC and ProLogium entered into a $50M PIPE subscription agreement with Naetas Holding Limited, securing 5M shares at…
425 — Impact 6/10
Jul 27, 2026 SEC
TDAC secured a $50M PIPE commitment from institutional investor Naetas Holding Limited, purchasing 5M shares at…
8-K — Impact 6/10
Jun 30, 2026 Inst.
LINDEN ADVISORS LP — ADD
1,150,000 shares ($12.3M)
Jun 30, 2026 Inst.
Centiva Capital, LP — ADD
250,000 shares ($2.7M)
May 27, 2026 Insider
Hoffman Michael B bought 53,395 shares
Chairman and CEO @ $0.7918 ($42.3K)

SecBot reports

5 filings · 2 bullish · 0 bearish · 3 neutral
All TDAC filing & press-release reports (5)